Table 46

Quantitative syntheses of short term harms and adherence data, for BAS plus statin therapy compared with statin monotherapy

Number of trials reporting outcomeNumber in relevant treatment groupsNumber of participants with eventsOdds ratioLower CIUpper CI
Treatment adherence
All trials122,133,137,164,190514201262
Simvastatin
Lower dose statin in combination versus higher dose monotherapy137181640.330.091.27
Atorvastatin
Lower dose statin in combination versus higher dose monotherapy133139350.940.127.48
At least one adverse event
All trials52,122,137,17245223012.191.283.75
All trials 24 weeks or more followup521150995.142.3911.07
Simvastatin
Lower dose statin in combination versus higher dose monotherapy137183441.190.473.02
Withdrawal due to adverse event
All trials52,122,133,164,172,185,191,1988966311.800.684.76
Atorvastatin
Lower dose statin in combination versus higher dose monotherapy13313921.060.0618.17
AST and/or ALT ≥ 3 times ULN, and/or hepatitis
All trials 185,19822120
Myalgia
All trials108,122,173,1854343110.430.121.54
CPK ≥ 10 times the ULN
All trials122,19821560

Abbreviations: ALT = alanine transaminase, AST = aspartate transaminase, BAS = bile acid sequestrant, CI = 95% confidence interval, CPK = creatinine phosphokinase

From: 3, Results

Cover of Comparative Effectiveness of Lipid-Modifying Agents
Comparative Effectiveness of Lipid-Modifying Agents [Internet].
Comparative Effectiveness Reviews, No. 16.
Sharma M, Ansari MT, Soares-Weiser K, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.